Dynamic Technology Lab Private Ltd Buys New Holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Dynamic Technology Lab Private Ltd purchased a new position in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) in the 3rd quarter, Holdings Channel.com reports. The fund purchased 13,134 shares of the company’s stock, valued at approximately $286,000.

Other large investors also recently modified their holdings of the company. Rhumbline Advisers boosted its position in Fulgent Genetics by 0.9% during the 2nd quarter. Rhumbline Advisers now owns 68,210 shares of the company’s stock worth $1,338,000 after purchasing an additional 637 shares during the period. Signaturefd LLC lifted its stake in shares of Fulgent Genetics by 103.6% during the second quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock worth $44,000 after purchasing an additional 1,132 shares in the last quarter. Marquette Asset Management LLC boosted its position in shares of Fulgent Genetics by 13.7% in the third quarter. Marquette Asset Management LLC now owns 9,908 shares of the company’s stock worth $215,000 after buying an additional 1,191 shares during the period. Asset Dedication LLC acquired a new stake in shares of Fulgent Genetics in the second quarter valued at about $33,000. Finally, nVerses Capital LLC acquired a new position in Fulgent Genetics during the 2nd quarter worth approximately $43,000. 48.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on FLGT. Piper Sandler reduced their target price on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating on the stock in a research report on Monday, November 11th. StockNews.com lowered shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a report on Wednesday, November 27th.

Fulgent Genetics Stock Up 1.3 %

FLGT stock opened at $18.30 on Monday. Fulgent Genetics, Inc. has a 52-week low of $16.56 and a 52-week high of $30.68. The stock’s 50 day moving average is $19.79 and its two-hundred day moving average is $21.09. The company has a market capitalization of $559.80 million, a PE ratio of -3.32 and a beta of 1.51.

Insider Transactions at Fulgent Genetics

In related news, CEO Ming Hsieh sold 2,227 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $18.26, for a total value of $40,665.02. Following the sale, the chief executive officer now directly owns 703,711 shares of the company’s stock, valued at $12,849,762.86. This represents a 0.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders sold 3,413 shares of company stock valued at $62,321. 31.76% of the stock is currently owned by corporate insiders.

Fulgent Genetics Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.